+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
NURECA

Nureca Share Price

 

 

Nureca live price: ₹232.1. It opened at ₹231 vs previous close ₹231; intraday high/low: ₹233/₹230. The 50 & 200 DMA stand at ₹257.47/₹266.97.

Nureca Performance

  • Today's Low
  • ₹230
  • Today's High
  • ₹233
  • 52 Week Low
  • ₹204
  • 52 Week High
  • ₹343
  • Open Price₹231
  • Previous Close₹231
  • Volume5,053
  • 50 DMA₹257.47
  • 100 DMA₹263.16
  • 200 DMA₹266.97

Nureca Chart

Investment Returns

  • Over 1 Month -14.59%
  • Over 3 Month -13.36%
  • Over 6 Month -21.97%
  • Over 1 Year -18.78%

Smart Investing Starts Here Start SIP with Nureca for Steady Growth!

Invest Now

Nureca Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 111.4
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 232
  • P/B Ratio
  • 1.3
  • Average True Range
  • 10.36
  • EPS
  • 2.18
  • Dividend Yield
  • 0
  • MACD Signal
  • -7.69
  • RSI
  • 35.25
  • MFI
  • 18.6

Latest Stock News Updates

Nureca shares hit 5% upper circuit as board to consider buyback on Nov 28

The company was supposed to consider a buyback in a meeting on November 10, 2025, which was then postponed due to the non-availability of the majority of the Independent Directors of the company

Nureca Standalone June 2023 Net Sales at Rs 21.23 crore, down 18.53% Y-o-Y

Nureca Standalone December 2022 Net Sales at Rs 27.84 crore, down 42.1% Y-o-Y

NULL

Nureca Financials

Nureca Technicals

EMA & SMA

Current Price
₹232.10
+ 1.6 (0.69%)
pointer
  • Bearish Moving Average 15
  • Bullish Moving Average 1
  • 20 Day
  • ₹247.60
  • 50 Day
  • ₹257.50
  • 100 Day
  • ₹263.20
  • 200 Day
  • ₹267.00

Resistance and Support

231.85 Pivot Speed
  • R3 237.15
  • R2 235.30
  • R1 233.70
  • S1 230.25
  • S2 228.40
  • S3 226.80

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Nureca has an operating revenue of Rs. 146.96 Cr. on a trailing 12-month basis. An annual revenue growth of 27% is outstanding, Pre-tax margin of 3% needs improvement, ROE of 1% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 23 which is a POOR score indicating inconsistency in earnings, a RS Rating of 25 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 29 indicates it belongs to a strong industry group of Medical-Products and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Nureca Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-29 Audited Results
2026-01-17 Quarterly Results & Others To consider other business matters. per share(20%)Final Dividend
2025-11-28 Buy Back of Shares
2025-11-10 Buy Back of Shares
2025-10-16 Quarterly Results & Others To consider other business matters. per share(20%)Final Dividend
Date Purpose Remarks
2022-02-25 INTERIM Rs.3.00 per share(30%)Interim Dividend
View Nureca Dividend History Arrow

Nureca Shareholding Pattern

68.09%
0.28%
28.83%
2.8%

Nureca FAQs

Nureca share price is ₹232 As on 13 June, 2026 | 18:16

The Market Cap of Nureca is ₹232.1 Cr As on 13 June, 2026 | 18:16

The P/E ratio of Nureca is 111.4 As on 13 June, 2026 | 18:16

The PB ratio of Nureca is 1.3 As on 13 June, 2026 | 18:16

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23